

1 **Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated**  
2 **Individuals with High-Risk Comorbidities**

3 <sup>1</sup>Dennis M. Bierle, <sup>1</sup>Ravindra Ganesh, <sup>1</sup>Sidna Tullidge-Scheitel, <sup>2</sup>Sara N. Hanson, <sup>3</sup>Lori L. Arndt, <sup>4</sup>Caroline  
4 G. Wilker, <sup>1</sup>Raymund R. Razonable

5 <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Mayo Clinic Health Systems, Mankato, MN, <sup>3</sup>Mayo Clinic Health Systems,  
6 Eau Claire, WI, and <sup>4</sup>Mayo Clinic Health Systems – Franciscan Healthcare, LaCrosse, WI

7 **Short title:** Monoclonal antibody for breakthrough COVID-19

8 **Word count** text: 1795 words, abstract: 100 words, references: 14, Tables: 2 (one supplementary table)

9 **Keywords:** breakthrough covid-19, casirivimab-imdevimab, vaccination, covid-19, SARS-CoV-2, outcome,  
10 hospitalization

11

12

13 **Correspondence:**

14 Raymund R Razonable, MD

15 Division of Infectious Diseases

16 Mayo Clinic

17 200 First Street SW, Rochester, MN 55905

18 [Razonable.raymund@mayo.edu](mailto:Razonable.raymund@mayo.edu)

19

20

21 **40-word summary**

22 Breakthrough COVID-19 may occur among vaccinated individuals with a high number of medical  
23 comorbidities, especially during the surge of SARS-CoV-2 Delta variant. Treatment with anti-spike  
24 monoclonal antibody was associated with significantly lower rates of hospitalization and oxygen  
25 supplementation.

26

27 **Abstract**

28 Breakthrough COVID-19 may occur in fully vaccinated persons. In this cohort of 1395 persons (mean age,  
29 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID-19, there  
30 were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated  
31 with the number of medical comorbidities. Anti-spike monoclonal antibody treatment was significantly  
32 associated with a lower risk of hospitalization (Odds Ratio: 0.227; 95% confidence interval, 0.128 - 0.403;  
33  $p < 0.001$ ). The number needed to treat to prevent one hospitalization was 225 among the lowest-risk  
34 patient group compared to 4 among the groups with highest numbers of medical comorbidity.

35 **Keywords:** breakthrough covid-19, casirivimab, imdevimab, hospitalization, outcomes, vaccination

36 **Footnotes**

37 **Funding:** Mayo Clinic

38 **Ethical approval:** This study was approved by the Mayo Clinic Institutional Review Board.

39 **Conflict of Interest Statement:**

40 Dr. Razonable is principal investigator of research funded by Regeneron, Roche, Gilead (all funds  
41 provided to his institution), and is a member of Data Safety Monitoring Board of Novartis, on projects  
42 not directly related to this submission. Dr. Razonable received research funds from the Mayo Clinic for  
43 studies on monoclonal antibodies for COVID-19.

44 All other authors: no conflict to report.

45

## 46 **Introduction**

47 COVID-19 vaccination is the primary strategy to reduce severe acute respiratory syndrome  
48 coronavirus 2 (SARS-CoV-2) outbreaks and its great burden to healthcare systems<sup>1</sup>. Clinical trial and  
49 real-world experience suggest high efficacy of SARS-CoV-2 vaccine for the prevention of COVID-19<sup>1,2,3</sup>.  
50 Despite the effectiveness of COVID-19 vaccines, breakthrough infections have been reported<sup>4</sup>. Among  
51 healthcare workers with breakthrough COVID-19, the majority of infections were mild, although 19%  
52 had persistent symptoms<sup>4</sup>. With the surge in SARS-CoV-2 B.1.617.2 (Delta) variant, there have been  
53 increasing reports of breakthrough infections among vaccinated persons.

54 Real-world clinical data are needed to characterize breakthrough COVID-19 in fully vaccinated  
55 persons and assess their risk of hospitalization. Moreover, there is no data as to whether vaccinated  
56 individuals with breakthrough COVID-19 would benefit from passive immunotherapy with casirivimab-  
57 imdevimab or bamlanivimab-etesevimab. In this study, we assessed the clinical outcomes of 1395 fully  
58 vaccinated adult patients with breakthrough COVID-19. We specifically investigated the rates of severe  
59 disease, as measured by oxygen requirement and need for hospitalization, and we compared these  
60 outcomes between patients who received or did not receive treatment with anti-spike monoclonal  
61 antibody.

## 62 **Methods**

### 63 *Patient Population and Study Design*

64 After approval by the Mayo Clinic Institutional Review Board, this retrospective study enrolled  
65 fully vaccinated patients with breakthrough COVID-19 who were screened for eligibility for treatment  
66 with bamlanivimab (Eli Lilly, Indianapolis, IN), bamlanivimab-etesevimab (Eli Lilly, Indianapolis, IN) or  
67 casirivimab-imdevimab (Regeneron, New York) as single infusion from January to August 16, 2021. All

68 patients developed PCR-confirmed breakthrough COVID-19 at least 2 weeks after the second of two  
69 doses of SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech or Moderna) or the single dose of Ad26.COV2.S  
70 (Johnson and Johnson) vaccine.

71 All patients were identified after being screened by the Mayo Clinic Monoclonal Antibody  
72 Treatment Program in Mayo Clinic sites in the Midwest, as previously described.<sup>5</sup> All patients had at  
73 least 28 days of follow up after the COVID-19 diagnosis. Only patients who provided authorization for  
74 the use of their medical records for research purposes were included. The conduct of this study was in  
75 compliance with the aims of Strengthening the Reporting of Observational Studies in Epidemiology  
76 (STROBE)<sup>6</sup>.

#### 77 *Clinical Variables*

78 The demographic and clinical characteristics of all patients, including COVID-19 vaccination  
79 status and date of vaccination, were collected by a review of their Electronic Health Records. Medical  
80 comorbidities and other characteristics that portend high-risk for progression to severe COVID-19 were  
81 recorded. The degree of medical comorbidity was assessed using Monoclonal Antibody Screening Score  
82 (MASS), a clinical criteria for risk of severe outcomes that has been previously described<sup>7,8</sup>. MASS  
83 assigned points to characteristics and comorbidity that made a person eligible for monoclonal antibody,  
84 according to the initial Food and Drug Administration (FDA) Emergency Use Authorization (EUA)  
85 guidance issued in November 2020<sup>9</sup>. In May 2021, the US FDA expanded the use of monoclonal  
86 antibodies to include lower-risk persons such as those with body mass index of 25 kg/m<sup>2</sup>. For the  
87 purposes of this study, MASS was used as a measure of medical comorbidity burden, as previously  
88 described<sup>7,8</sup>.

#### 89 *Clinical Outcomes*

90           The primary outcome for this study was the rate of all-cause hospitalization by day 28 after the  
91 diagnosis of breakthrough COVID-19. The need for oxygen supplementation was recorded as an  
92 indicator of severe disease. All 1395 patients had completed at least 28 days of follow up by the end of  
93 this study on September 15, 2021.

#### 94 *Statistical Analysis*

95           Data are presented in aggregate using descriptive statistics. The differences in the outcomes  
96 between two subgroups of patients, defined based on receipt or non-receipt of monoclonal antibodies,  
97 were compared using descriptive statistics. To calculate the proportion of patients who experienced 28-  
98 day hospitalization or use of oxygen supplementation, each patient who experienced one of the two  
99 outcomes was assigned to the numerator with the total population as the denominator. Simple  
100 proportions were calculated by receipt of monoclonal antibody therapy and stratified by MASS score.  
101 Differences in these proportions were assessed using Chi Square test for independence for categorical  
102 variables or a t-test for continuous variables after ensuring testing parameters were met. Fisher Exact  
103 test was used if testing assumptions were not achieved. Crude odds ratios (OR) with 95% confidence  
104 intervals (CIs), absolute risk reduction and number needed to treat were calculated to compare  
105 associations of patient characteristics with outcomes;  $P < 0.05$  was deemed statistically significant. The  
106 association between monoclonal antibody therapy and hospitalization within 28 days was assessed with  
107 logistic regression with adjustment for MASS. Data was analyzed using Microsoft Excel (Microsoft Excel  
108 for Office 365, Version 16.0.13127.21766, Microsoft Corporation, Redmond, WA) and BlueSky Statistics  
109 (Commercial Server Edition, Version 7.40).

#### 110 **Results**

111           The total population consisted of 1395 fully vaccinated patients (mean age, 54.3 years; 39.6%  
112 male) with breakthrough COVID-19 and were screened for monoclonal antibody therapy, under US FDA

113 EUA guidance. The majority of breakthrough SARS-CoV-2 infections (n=1002; 71.8%) occurred during a  
114 6-week period from July 1 to August 16, 2021, when the Delta variant was predominant in our region.  
115 The most common medical comorbidities were hypertension (34.5%), cardiovascular disease (13.8%),  
116 chronic pulmonary disease (13.6%), chronic kidney disease (10.2%), and cancer (10.7%) (**Table 1**). Most  
117 patients (69.8%) received the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine.

118 Breakthrough COVID-19 occurred at mean of 120 days after full completion of the vaccination  
119 series. At 28 days after breakthrough COVID-19 diagnosis, 107 patients (7.7%) had progressed to require  
120 hospitalization. The rate of hospitalization was significantly higher among patients with higher medical  
121 comorbidity score (**Table 2** and **Supplementary Table**).

122 **Table 2** stratifies the population into those who received (n=527; 37.8%) versus those who did  
123 not receive (n=868; 62.2%) treatment with anti-spike monoclonal antibody. Among those who received  
124 treatment, the majority were treated with casirivimab-imdevimab, including all patients diagnosed after  
125 May 7, 2021. Patients received the monoclonal antibody treatment at a median of 5 days (interquartile  
126 range, 3-6 days) from symptom onset and 2 days (interquartile range, 1-3 days) from testing. Overall,  
127 the rate of hospitalization was 2.65% among patients treated with monoclonal antibody compared to  
128 10.7% among those who did not receive therapy (Odds Ratio [OR]: 0.227; 95% confidence [CI] interval,  
129 0.128 - 0.403; p<0.001). Controlling for MASS, monoclonal antibody therapy was associated with a lower  
130 rate of hospitalization (OR: 0.14; 95% CI, 0.079-0.265; p<0.0001). The number needed to treat (NNT) to  
131 prevent one hospitalization correlated with the degree of medical comorbidity. NNT was 255 among  
132 vaccinated persons without high-risk medical comorbidity while NNT was between 3 and 8 among  
133 patients with multiple high-risk medical conditions (**Table 3**, polled NNT of 4 for patient groups with  
134 MASS  $\geq$ 4).



135           Sixty-one patients (4.4%) developed hypoxia and required oxygen supplementation. Anti-spike  
136 monoclonal antibody treatment was significantly associated with lower rates of hypoxia when compared  
137 to those who did not received monoclonal antibody (0.95% versus 6.45%; OR, 0.139; 95% CI, 0.055 –  
138 0.349;  $p < 0.001$ ). The majority ( $n=56$ ; 91.8%) of patients who required oxygen supplementation did not  
139 receive monoclonal antibody treatment. Five (0.36%) patients required admission to the intensive care  
140 unit (ICU), none of whom were treated with monoclonal antibody. No death was reported among 1395  
141 vaccinated patients with breakthrough COVID-19.

## 142 **Discussion**

143           This study provides several observations that are relevant in the current era of the SARS-CoV-2  
144 pandemic that is dominated by the Delta variant causing breakthrough COVID-19 in fully vaccinated  
145 individuals. First, this study observed that, among patients with breakthrough COVID-19, 8% developed  
146 clinical progression to require hospitalization, including some needing oxygen supplementation. This  
147 finding emphasizes the need for other public health strategies (e.g., use of face mask and avoidance of  
148 large gatherings) for all individuals, even among vaccinated individuals, during periods characterized by  
149 high community SARS-CoV-2 Delta transmission.

150           Second, this study demonstrates that the risk of hospitalization among breakthrough COVID-19  
151 cases varies according to the degree of medical comorbidity. In our cohort, obesity, hypertension,  
152 diabetes, cancer, chronic lung, kidney and cardiac conditions accounted for majority of comorbidities.  
153 This study demonstrates that individuals who possessed multiple comorbidities, as measured by MASS,  
154 were at higher risk of hospitalization. Some of the multi-comorbidity patients in this study included  
155 those with cancer and immune compromised patients who may have suboptimal response to COVID-19  
156 vaccine. This finding supports the current FDA EUA for post exposure prophylaxis in high risk patients

157 who have been fully immunized but are at high risk of not mounting a robust immune response  
158 secondary to immunocompromised state.

159 Third, this study provides clinical evidence of the benefit of augmented passive immunotherapy  
160 among fully vaccinated patients with breakthrough COVID-19. This benefit is especially evident among  
161 those with a high number of medical comorbidities. As indicated above, it is possible that these high-risk  
162 individuals may have had suboptimal response to COVID-19 vaccine. Supplementing these patients with  
163 monoclonal antibody immunotherapy may have mitigated their risk of clinical disease progression<sup>10</sup>.  
164 Monoclonal antibody treatment of breakthrough COVID-19 resulted in a lower risk of hospitalization,  
165 and a reduced need for oxygen supplementation among hospitalized patients. This observation is  
166 consistent with our previous report that associated monoclonal antibody treatment with reduced rates  
167 of hospitalization compared to those who did not receive treatment<sup>11,12</sup>. The vast majority of our cohort  
168 developed breakthrough COVID-19 during the Delta surge, and this finding provides the clinical correlate  
169 to experimental data that suggested that casirivimab-imdevimab combination (which was used solely  
170 after May 7, 2021) retains efficacy against SARS-CoV-2 B.1.617.2, which is assumed as main cause of the  
171 breakthrough cases<sup>13,14</sup>.

172 This was a retrospective study with the inherent limitations to this study design. For example,  
173 we would not have captured treated patients who may have been hospitalized at outside institutions.  
174 However, we believe that this is not a considerable number since our program enrolls high-risk patients  
175 to a remote monitoring program, thereby ensuring continued contact with these patients until symptom  
176 resolution<sup>5</sup>. Our population was predominantly Caucasian, and our findings may not be generalizable to  
177 other patient populations. Most patients received treatment with casirivimab-imdevimab, limiting  
178 generalizability to other monoclonal antibodies such as bamlanivimab-etesevimab and sotrovimab. The  
179 study observations should also be interpreted in the context that it was performed in patients screened

180 and treated in a single healthcare system. These limitations are counterbalanced by having a relatively  
181 large cohort of breakthrough COVID-19 cases identified in our healthcare system, with many identified  
182 during the period of the Delta surge. This large patient cohort allowed for robust statistical analysis of  
183 the potential efficacy of treatment with monoclonal antibody therapy.

#### 184 **Conclusion**

185 Fully vaccinated persons, particularly those with multiple medical comorbidities, may develop  
186 breakthrough COVID-19, especially during the surge of a more communicable Delta variant. Some  
187 patients progressed to severe COVID-19 that required hospitalization, including the need of oxygen  
188 supplementation and ICU care. The severity of breakthrough COVID-19 significantly correlated with a  
189 high number of medical comorbidities. Reassuringly, no death was reported. Early treatment with anti-  
190 spike monoclonal antibody was associated with a significantly lower rate of severe COVID-19 that would  
191 require hospitalization.

192

193    **Acknowledgments:** The author would like to thank all members of the Mayo Clinic Monoclonal Antibody  
194    Treatment Program.

195

196 **References:**

- 197 1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the  
198 B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; **385**(7): 585-94.
- 199 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2  
200 Vaccine. *N Engl J Med* 2021; **384**(5): 403-16.
- 201 3. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of Messenger RNA Coronavirus Disease 2019  
202 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection  
203 in a Cohort of Healthcare Personnel. *Clin Infect Dis* 2021; **73**(6): e1376-e9.
- 204 4. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health  
205 Care Workers. *N Engl J Med* 2021.
- 206 5. Razonable RR, Aloia NCE, Anderson RJ, et al. A Framework for Outpatient Infusion of Antispikes  
207 Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo  
208 Clinic Model. *Mayo Clin Proc* 2021; **96**(5): 1250-61.
- 209 6. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies  
210 in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;  
211 **370**(9596): 1453-7.
- 212 7. Ganesh R, Philpot LM, Bierle DM, et al. Real-World Clinical Outcomes of Bamlanivimab and  
213 Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019. *J*  
214 *Infect Dis* 2021.
- 215 8. Bierle DM, Ganesh R, Wilker CG, et al. Influence of Social and Cultural Factors on the Decision to  
216 Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. *J*  
217 *Prim Care Community Health* 2021; **12**: 21501327211019282.
- 218 9. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. *JAMA* 2020.

- 219 10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail,  
220 in Outpatients with Covid-19. *N Engl J Med* 2020.
- 221 11. Razonable RR, Pawlowski C, O'Horo JC, Bierle D, Arndt L, Arndt R. Casirivimab-Imdevimab  
222 Treatment is Associated with Reduced Rates of Hospitalization among High-Risk Patients with Mild to  
223 Moderate Coronavirus Disease-19. *EClinicalMedicine* 2021.
- 224 12. Ganesh R, Pawlowski CF, O'Horo JC, et al. Intravenous bamlanivimab use associates with  
225 reduced hospitalization in high-risk patients with mild to moderate COVID-19. *J Clin Invest* 2021.
- 226 13. 2021. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>.
- 227 14. Wilhelm A, Toptan T, Pallas C, et al. Antibody-Mediated Neutralization of Authentic SARS-CoV-2  
228 B.1.617 Variants Harboring L452R and T478K/E484Q. *Viruses* 2021; **13**(9).

229

230

231 **Table 1.** Demographic and Clinical Characteristics of 1395 Vaccinated Persons with Breakthrough  
 232 Coronavirus Disease-2019, Mayo Clinic in the Midwest, January 1 – August 16, 2021

<b>Characteristics</b>	<b>Number of patients (percentage), unless otherwise specified</b>
Age, in years, mean $\pm$ standard deviation	54.3 $\pm$ 18.5
Male sex	553 (39.64%)
Body mass index, mean $\pm$ standard deviation	30.7 $\pm$ 8.8
Cancer	149 (10.68%)
Cardiac disease	192 (13.76%)
Chronic kidney disease	142 (10.18%)
Diabetes mellitus	208 (14.91%)
Hypertension	481 (34.48%)
Pulmonary disease	190 (13.62%)
Covid-19 vaccine type	
Ad26.COV2.S vaccine (Johnson and Johnson)	133 (9.53%)
BNT162b2 vaccine (Pfizer-BioNTech)	974 (69.82%)
mRNA-1273 vaccine (Moderna)	288 (20.65%)
Time between full vaccination date and breakthrough COVID-19, in days; mean $\pm$ standard deviation	120 $\pm$ 53.7
Monoclonal antibody treatment	
Bamlanivimab or bamlanivimab-etesevimab	43 (3.08%)
Casirivimab-imdevimab	484 (34.70%)
No treatment	868 (62.22%)

233

234

235 **Table 2.** Differences in Rates of Hospitalization among 1395 Vaccinated Persons with Breakthrough  
 236 Coronavirus Disease-2019 According to Treatment with Anti-spike Monoclonal Antibody

MASS*	Monoclonal antibody treatment		No treatment		Relative Risk	Odds Ratio (95% CI)	Absolute Risk Reduction	NNT
	Number (hospitalized)	Rate	Number (hospitalized)	Rate				
0	117 (2)	0.017	428 (9)	0.021	0.813	0.809 (0.173-3.800)	0.004	255
1	83 (0)	0	86 (2)	0.023	0	0.202 (0.010-4.280)	0.023	43
2	49 (1)	0.020	60 (4)	0.067	0.306	0.292 (0.032-2.700)	0.046	22
3	92 (3)	0.032	57 (7)	0.123	0.266	0.241 (0.060-0.973)	0.090	12
4	39 (0)	0	53 (8)	0.151	0	0.068 (0.125-0.028)	0.151	7
≥4 (pooled)	186 (8)	0.043	237 (71)	0.300	0.143	0.105 (0.049-0.225)	0.257	4
5	41 (2)	0.048	72 (21)	0.292	0.167	0.125 (0.243-0.040)	0.243	5
6	37 (2)	0.054	21 (4)	0.190	0.284	0.243 (0.152-0.031)	0.136	8
7	26 (2)	0.076	34 (12)	0.353	0.218	0.153 (0.058-0.128)	0.276	4
≥8 (pooled)	43 (2)	0.046	57 (26)	0.456	0.102	0.058 (0.013-0.264)	0.409	3

237 \*MASS assigned a score to each of the FDA EUA eligibility criteria (November 2020), as follows: age ≥65  
 238 (2 points), BMI ≥35 (1 point), diabetes mellitus (2 points), chronic kidney disease (3 points),  
 239 cardiovascular disease in a patient ≥55 years (2 points), chronic respiratory disease in a patient ≥55  
 240 years (2 points), hypertension in a patient ≥55 years (1 point), and immunocompromised status (3  
 241 points).

242

243



244 **Supplementary Table.** Rates of Hospitalization among 1395 Vaccinated Individuals with Breakthrough  
 245 Coronavirus Disease-2019, Stratified Based on Monoclonal Antibody Screening Score

Monoclonal Antibody Screening Score (MASS)	Number of Patients	Number of Hospitalized Patients	Odds Ratio (95% Confidence Interval)	P value
0	545	11	1	-
1	169	2	0.58 (0.13-2.65)	0.478
2	109	5	2.33 (0.79-6.86)	0.113
3	149	10	3.49 (1.45-8.39)	0.003
4	92	8	4.6 (1.81-11.83)	< 0.001
5	113	23	12.41 (5.85-26.33)	< 0.001
6	58	6	5.60 (1.99-15.76)	< 0.001
7	60	14	14.77 (6.35-34.40)	< 0.001
8	41	9	13.65 (5.28-35.32)	< 0.001
9	17	8	43.15 (14.02-132.79)	< 0.001
10	25	7	18.88 (6.56-54.36)	< 0.001
11	11	3	18.20 (4.25-78.00)	< 0.001
12	4	1	16.18 (1.55-168.09)	< 0.001
13	2	0	0	0.8392
Total	1395	107		

246 MASS assigned a score to each of the FDA EUA eligibility criteria (November 2020), as follows: age  $\geq 65$  (2  
 247 points), BMI  $\geq 35$  (1 point), diabetes mellitus (2 points), chronic kidney disease (3 points), cardiovascular  
 248 disease in a patient  $\geq 55$  years (2 points), chronic respiratory disease in a patient  $\geq 55$  years (2 points),  
 249 hypertension in a patient  $\geq 55$  years (1 point), and immunocompromised status (3 points).

250

251